RhumbLine Advisers’s Cytek Biosciences CTKB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$991K Buy
166,196
+12,971
+8% +$61.5K ﹤0.01% 2276
2026
Q2
$679K Sell
153,225
-101,364
-40% -$433K ﹤0.01% 2559
2026
Q1
$1.11M Buy
254,589
+4,649
+2% +$21.9K ﹤0.01% 2143
2025
Q4
$1.26M Sell
249,940
-30,427
-11% -$141K ﹤0.01% 2110
2025
Q3
$973K Sell
280,367
-2,284
-0.8% -$8.57K ﹤0.01% 2261
2025
Q2
$961K Sell
282,651
-13,633
-5% -$45.4K ﹤0.01% 2268
2025
Q1
$1.19M Buy
296,284
+1,745
+0.6% +$9.04K ﹤0.01% 2090
2024
Q4
$1.91M Buy
294,539
+14
+0% +$83 ﹤0.01% 1901
2024
Q3
$1.63M Sell
294,525
-60,911
-17% -$345K ﹤0.01% 2016
2024
Q2
$1.98M Buy
355,436
+18,124
+5% +$109K ﹤0.01% 1891
2024
Q1
$2.26M Buy
337,312
+9,682
+3% +$76.6K ﹤0.01% 1849
2023
Q4
$2.99M Buy
327,630
+5,638
+2% +$35.5K ﹤0.01% 1702
2023
Q3
$1.78M Buy
321,992
+31,570
+11% +$253K ﹤0.01% 1912
2023
Q2
$2.48M Buy
290,422
+141,055
+94% +$1.27M ﹤0.01% 1787
2023
Q1
$1.37M Buy
149,367
+6,804
+5% +$73.2K ﹤0.01% 1998
2022
Q4
$1.46M Buy
142,563
+1,845
+1% +$24.8K ﹤0.01% 1947
2022
Q3
$2.07M Buy
140,718
+11,751
+9% +$153K ﹤0.01% 1741
2022
Q2
$1.38M Buy
128,967
+32,689
+34% +$325K ﹤0.01% 1960
2022
Q1
$1.04M Buy
96,278
+81,455
+550% +$1.1M ﹤0.01% 2117
2021
Q4
$242K Buy
14,823
+3,062
+26% +$64.1K ﹤0.01% 2775
2021
Q3
$252K Buy
+11,761
New +$277K ﹤0.01% 2836

Other funds holding CTKB

RhumbLine Advisers's CTKB Position: Q3 2026 in Review

RhumbLine Advisers increased its Cytek Biosciences (CTKB) stake by 8.5% in Q3 2026, buying an estimated $61.5K and bringing the position to 166,196 shares worth $991K. The position accounts for ﹤0.01% of the portfolio, ranked #2276.

RhumbLine Advisers first reported a position in CTKB in Q3 2021 and has held it in 21 quarters since. The position peaked at $2.99M in Q4 2023. 150 funds tracked by Wall St. Rank hold CTKB as of Q3 2026.

  • RhumbLine Advisers held 166,196 shares of Cytek Biosciences worth $991K as of Q3 2026.
  • RhumbLine Advisers bought 12,971 Cytek Biosciences shares in Q3 2026, an estimated $61.5K.
  • Cytek Biosciences made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #2276 holding.
  • RhumbLine Advisers first reported a position in Cytek Biosciences in Q3 2021 and has held it in 21 quarters since.
  • RhumbLine Advisers's Cytek Biosciences position peaked at $2.99M in Q4 2023.
  • 150 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.